Focused On-demand Library for Serine hydrolase RBBP9

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O75884

UPID:

RBBP9_HUMAN

Alternative names:

B5T-overexpressed gene protein; Retinoblastoma-binding protein 10; Retinoblastoma-binding protein 9

Alternative UPACC:

O75884; D3DW31; Q5JPH9; Q9H1D8

Background:

Serine hydrolase RBBP9, also known as Retinoblastoma-binding protein 9, plays a crucial role in cellular processes. Its substrates remain unidentified, yet it is known to negatively regulate TGF-beta signaling, impacting SMAD2-SMAD3 phosphorylation. This protein's interaction with RB1 and displacement of E2F1 suggests a significant role in cellular transformation and resistance to TGF-beta's growth-inhibitory effects.

Therapeutic significance:

Understanding the role of Serine hydrolase RBBP9 could open doors to potential therapeutic strategies. Its involvement in key signaling pathways and cellular transformation processes highlights its potential as a target for drug discovery, aiming to modulate TGF-beta signaling in disease contexts.